Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery

Status unconfirmed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with stage III or stage IV kidney cancer that has been removed by surgery.

Key facts

Study ID

NCT00003604

Run by

Cancer Biotherapy Research Group

People needed

20

Starts

1997-10-01

Last updated by the study team

2013-11-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cancer Care Center for Southern Indiana — Bloomington, Indiana, United States
• Bergan Mercy Medical Center — Omaha, Nebraska, United States
• Baptist Regional Cancer Center - Knoxville — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.